Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

444 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Chataway J, De Angelis F, Connick P, Parker RA, Plantone D, Doshi A, John N, Stutters J, MacManus D, Prados Carrasco F, Barkhof F, Ourselin S, Braisher M, Ross M, Cranswick G, Pavitt SH, Giovannoni G, Gandini Wheeler-Kingshott CA, Hawkins C, Sharrack B, Bastow R, Weir CJ, Stallard N, Chandran S; MS-SMART Investigators. Chataway J, et al. Among authors: john n. Lancet Neurol. 2020 Mar;19(3):214-225. doi: 10.1016/S1474-4422(19)30485-5. Epub 2020 Jan 22. Lancet Neurol. 2020. PMID: 31981516 Free PMC article. Clinical Trial.
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis.
Connick P, De Angelis F, Parker RA, Plantone D, Doshi A, John N, Stutters J, MacManus D, Prados Carrasco F, Barkhof F, Ourselin S, Braisher M, Ross M, Cranswick G, Pavitt SH, Giovannoni G, Gandini Wheeler-Kingshott CA, Hawkins C, Sharrack B, Bastow R, Weir CJ, Stallard N, Chandran S, Chataway J; UK Multiple Sclerosis Society Clinical Trials Network. Connick P, et al. Among authors: john n. BMJ Open. 2018 Aug 30;8(8):e021944. doi: 10.1136/bmjopen-2018-021944. BMJ Open. 2018. PMID: 30166303 Free PMC article. Clinical Trial.
Practical approach to the diagnosis of adult-onset leukodystrophies: an updated guide in the genomic era.
Lynch DS, Wade C, Paiva ARB, John N, Kinsella JA, Merwick Á, Ahmed RM, Warren JD, Mummery CJ, Schott JM, Fox NC, Houlden H, Adams ME, Davagnanam I, Murphy E, Chataway J. Lynch DS, et al. Among authors: john n. J Neurol Neurosurg Psychiatry. 2019 May;90(5):543-554. doi: 10.1136/jnnp-2018-319481. Epub 2018 Nov 22. J Neurol Neurosurg Psychiatry. 2019. PMID: 30467211 Free PMC article. Review.
How to diagnose difficult white matter disorders.
Williams T, Houlden H, Murphy E, John N, Fox NC, Schott JM, Adams M, Davagananam I, Chataway J, Lynch DS. Williams T, et al. Among authors: john n. Pract Neurol. 2020 Aug;20(4):280-286. doi: 10.1136/practneurol-2020-002530. Epub 2020 May 20. Pract Neurol. 2020. PMID: 32434903 Review.
Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT.
De Angelis F, Connick P, Parker RA, Plantone D, Doshi A, John N, Stutters J, MacManus D, Prados F, Marshall I, Solanky B, Samson RS, Barkhof F, Ourselin S, Braisher M, Ross M, Cranswick G, Pavitt SH, Gnanapavan S, Giovannoni G, Wheeler-Kingshott CAMG, Hawkins C, Sharrack B, Bastow R, Weir CJ, Stallard N, Chandran S, Chataway J. De Angelis F, et al. Among authors: john n. Southampton (UK): NIHR Journals Library; 2020 May. Southampton (UK): NIHR Journals Library; 2020 May. PMID: 32453521 Free Books & Documents. Review.
MS-SMART study: systematic sampling bias concerns - Authors' reply.
Chataway J, De Angelis F, Connick P, Parker RA, Doshi A, John N, Barkhof F, Sharrack B, Weir CJ, Chandran S; MS-SMART Investigators. Chataway J, et al. Among authors: john n. Lancet Neurol. 2020 Jun;19(6):479-480. doi: 10.1016/S1474-4422(20)30149-6. Epub 2020 May 26. Lancet Neurol. 2020. PMID: 32470412 Free article. No abstract available.
NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study.
Solanky BS, John NA, DeAngelis F, Stutters J, Prados F, Schneider T, Parker RA, Weir CJ, Monteverdi A, Plantone D, Doshi A, MacManus D, Marshall I, Barkhof F, Gandini Wheeler-Kingshott CAM, Chataway J; MS-SMART Investigators. Solanky BS, et al. Among authors: john na. AJNR Am J Neuroradiol. 2020 Dec;41(12):2209-2218. doi: 10.3174/ajnr.A6809. Epub 2020 Nov 5. AJNR Am J Neuroradiol. 2020. PMID: 33154071 Free PMC article. Clinical Trial.
444 results